# Clinical Laboratory COVID-19 Response Call Monday, August 23, 2021, at 3:00 PM EDT

#### Welcome

- Jasmine Chaitram, CDC Division of Laboratory Systems (DLS)
- SARS-CoV-2 Variants Update
  - John Barnes, CDC Laboratory and Testing Task Force for the COVID-19 Response
- Testing and Diagnostics Working Group
  - Dean Winslow, U.S. Department of Health and Human Services (HHS) Testing and Diagnostics Working Group (TDWG)

#### FDA Update

Tim Stenzel, U.S. Food and Drug Administration (FDA)

# Division of Laboratory Systems (DLS)

## Vision

Exemplary laboratory science and practice advance clinical care, public health, and health equity.

### Mission

Improve public health, patient outcomes, and health equity by advancing clinical and public health laboratory quality and safety, data and biorepository science, and workforce competency.



#### Four Goal Areas of DLS









# Quality Laboratory Science

Improve the quality and value of laboratory medicine and biorepository science for better health outcomes and public health surveillance

#### Highly Competent Laboratory Workforce

Strengthen the laboratory workforce to support clinical and public health laboratory practice

# Safe and Prepared Laboratories

Enhance the safety and response capabilities of clinical and public health laboratories


# Accessible and Usable Laboratory Data

Increase access and use of laboratory data to support response, surveillance, and patient care

# CDC Preparedness Portal

https://www.cdc.gov/csels/dls/preparedlabs/covid-19-clinical-calls.html

Find CLCR call information, transcripts, and audio recordings on the CDC Preparedness Portal



## Schedule for Clinical Laboratory COVID-19 Response Calls

The next call will be on Monday, September 20 from 3:00 PM to 4:00 PM EDT



#### We Want to Hear from You!

### **Training and Workforce Development**

Questions about education and training?

Contact <u>LabTrainingNeeds@cdc.gov</u>



## How to Ask a Question

- Using the Zoom Webinar System
  - Click the Q&A button in the Zoom webinar system
  - Type your question in the Q&A box and submit it
  - Please do not submit a question using the chat button





- For media questions, please contact CDC Media Relations at media@cdc.gov
- If you are a patient, please direct any questions to your healthcare provider

Slide decks may contain presentation material from panelists who are not affiliated with CDC. Presentation content from external panelists may not necessarily reflect CDC's official position on the topic(s) covered.


## **SSEV Update**

John R. Barnes, Ph.D.

SSEV Deputy Lead, COVID-19 Laboratory Task Force

Use of trade names and commercial sources is for identification only and does not imply endorsement by the Centers for Disease Control and Prevention or the U.S. Department of Health and Human Services.






cdc.gov/coronavirus

# National Nowcast Estimates of SARS-CoV-2 Lineages



- Delta (including sublineages) increased¹
  - From 94% to 99%
    - B.1.617.2 (86%)
    - AY.3 (12%), AY.2 (0.3%), AY.1 (0.1%)
- Alpha (B.1.1.7) decreased
  - from 2.4% to 0.3%
- Gamma (P.1) decreased
  - from 1% to 0.2%
- B.1.427 and B.1.429
  - no longer considered VOI
  - Less than 0.1% nationally

<sup>1</sup>Weighted estimates from period ending 07/24/2021 (as of 7/31/2021) used for comparison with Nowcast (as of 08/14/2021)




https://covid.cdc.gov/covid-data-tracker/#variant-proportions


## **Regional Nowcast Proportion of SARS-CoV-2** Lineages



- Delta (B.1.617.2) predominates in all HHS Regions
  - AY.3 is highest in Region 7 (38%)
  - AY.1 and AY.2 are less than 1% for all HHS Regions and nationally
  - Alpha (B.1.1.7) decreasing in all Regions
    - Less than 1% in each Region
- Gamma (P.1)
  - Decreasing in all HHS Regions
    - Less than 1% in each Region



https://covid.cdc.gov/covid-data-tracker/#variant-proportions



For more information, contact CDC 1-800-CDC-INFO (232-4636)

TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.



#### Center for Surveillance, Epidemiology, and Laboratory Services

### HHS Testing & Diagnostics Working Group (TDWG)

#### **Dean Winslow**

U.S. Department of Health and Human Services (HHS)
Testing and Diagnostics Working Group (TDWG)



#### Center for Surveillance, Epidemiology, and Laboratory Services

## FDA Update

#### **Tim Stenzel**

U.S. Food and Drug Administration (FDA)



#### CDC Social Media

https://www.facebook.com/CDC





https://twitter.com/cdcgov


https://www.instagram.com/cdcgov





https://www.linkedin.com/company/cdc

## Thank You For Your Time!



Division of Laboratory Systems Excellent Laboratories, Outstanding Health